From a broader molecular profiling viewpoint, the key determinants for guiding personalised, nanoparticle-enabled therapy in ovarian cancer are highlighted as multi-omic profiling of BRCA/HRD, HER2, FOLR1 and other targets [111]. The gene discussed is ERBB2; the disease is ovarian carcinoma.